XSpray Pharma AB (STU:6XP) EPS (Basic) : €-0.75 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB EPS (Basic)?

XSpray Pharma AB's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was €-0.21. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.75.

XSpray Pharma AB's EPS (Diluted) for the three months ended in Dec. 2024 was €-0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.75.

XSpray Pharma AB's EPS without NRI for the three months ended in Dec. 2024 was €-0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.75.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

XSpray Pharma AB EPS (Basic) Historical Data

The historical data trend for XSpray Pharma AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB EPS (Basic) Chart

XSpray Pharma AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.29

-0.48

-0.56

-0.60

-0.75

XSpray Pharma AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.17	-0.19	-0.14	-0.21	-0.21

XSpray Pharma AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

XSpray Pharma AB's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-24.822	-	0)	/	33.137
	=	-0.75

XSpray Pharma AB's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.126	-	0)	/	34.757
	=	-0.21

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.75

XSpray Pharma AB (STU:6XP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

XSpray Pharma AB EPS (Basic) Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

XSPRAY:Sweden 0GHZ:UK

Address

Scheeles vag 2, Solna, SWE, SE-171 65

Website

https://www.xspraypharma.com

XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines